Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?

Article Biotechnology & Applied Microbiology

Anticancer evaluation of methotrexate and curcumin coencapsulated niosomes against colorectal cancer cell line

Navid Mousazadeh et al.

Summary: The combination of CUR and MTX in niosomal formulation showed enhanced toxicity compared to their free form, indicating the potential of nanocarrier-based approach for codelivery against cancer cells in vitro.

NANOMEDICINE (2022)

添加到收藏夹

Article Oncology

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

Paolo Antonetti et al.

Summary: This study investigated the management of anti-EGFR-related cutaneous adverse events in a real-life clinical context for patients with metastatic colorectal cancer. The results showed a lower incidence of acneiform rash in the pre-emptive treatment group compared to the reactive treatment group, but a higher incidence of paronychia/nail disorders. Overall, the pre-emptive approach did not affect the efficacy of antineoplastic therapy.

SUPPORTIVE CARE IN CANCER (2022)

添加到收藏夹

Article Oncology

Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part)

Katsuko Kikuchi et al.

Summary: The study found no significant differences in the severity of facial acneiform eruption (FAfE) and adverse events caused by topical corticosteroids between the two groups over an 8-week period. However, the group starting with a strong corticosteroid showed lower incidence of grade 2 or higher FAfE during the first 2 weeks, suggesting that the regimen ranking up in potency may be more suitable for long-term management of FAfE due to EGFR inhibitor therapy.

SUPPORTIVE CARE IN CANCER (2022)

添加到收藏夹

Article Oncology

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

Laura E. Fischer et al.

Summary: The efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC), which may be attributed to the higher proportion of right-sided tumors and lower secondary resection rate in older patients. The efficacy of targeted therapy in older patients is dependent on the sidedness of the tumor.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location

Hitoshi Hino et al.

Summary: This study compared the genetic characteristics of low rectal cancer (RC) with other RCs. Low RC had a higher accumulation of KRAS mutations and significant differences in gene expression levels. The distribution of consensus molecular subtypes (CMS) and the prevalence of fusion genes were also significantly different in low RC. CMS4 was more frequent in low RC and associated with poor prognosis.

JOURNAL OF GASTROENTEROLOGY (2022)

添加到收藏夹

Article Oncology

Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial

Alessandra Raimondi et al.

Summary: In the study of RAS wild-type mCRC patients, age did not have a significant impact on survival outcomes when selecting maintenance strategies. However, younger patients showed a trend for increased chemotherapy-related adverse events, such as anemia, while experiencing significantly decreased EGFR-related hypomagnesemia and increased skin rash. Management of treatment-related adverse events should take into account the differential toxicity profile of age and sex.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Apigenin and its dermatological applications: A comprehensive review

Pantea Majma Sanaye et al.

Summary: This article provides an overview of the effects of apigenin on different dermatological complications and highlights its anti-inflammatory and antioxidant properties. Preclinical studies suggest that apigenin has beneficial effects on skin aging, vitiligo, dermatitis, wounds, and certain types of skin cancer. However, there is a lack of clinical studies evaluating the use of apigenin as a natural supplement for skin conditions.

PHYTOCHEMISTRY (2022)

添加到收藏夹

Article Oncology

Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab)

Rossella De Luca et al.

Summary: Skin toxicity, especially rash, in patients with metastatic colorectal cancer affects approximately 80% of patients and has a significant impact on their quality of life and social relationships, compromising therapeutic compliance.

WORLD JOURNAL OF ONCOLOGY (2021)

添加到收藏夹

Review Dermatology

Vitamin E supplementation in inflammatory skin diseases

Enzo Berardesca et al.

Summary: Vitamin E is a powerful antioxidant that protects against oxidative damage and neurodegenerative diseases. Supplementation of vitamin E can be beneficial in certain cases and chronic diseases. While some studies suggest a positive role of vitamin E in atopic dermatitis and psoriasis, further research is needed to confirm its efficacy.

DERMATOLOGIC THERAPY (2021)

添加到收藏夹

Article Oncology

Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study

Alessandra Raimondi et al.

Summary: The prophylactic use of doxycycline for anti-EGFR-related skin toxicity did not significantly affect the rate of overall adverse events and skin rash occurrence in mCRC patients. Subpopulations with and without prophylaxis showed no significant differences in treatment duration, delays or dose reductions, PFS, and OS in the Valentino study.

SUPPORTIVE CARE IN CANCER (2021)

添加到收藏夹

Article Dermatology

Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial

Keita Tsutsui et al.

Summary: The study evaluated the efficacy and safety of topical benzoyl peroxide for treating epidermal growth factor receptor inhibitor-induced prolonged acneiform eruptions. Results showed potential in improving acneiform eruption severity and patients' quality of life.

JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Oncology

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy

Davide Ciardiello et al.

Summary: Skin toxicity serves as a crucial biomarker for predicting response to anti-EGFR rechallenge treatment in metastatic colorectal cancer patients. High-grade skin toxicity, along with circulating tumor DNA RAS/BRAF/EGFR wild-type status, significantly impacts progression-free survival and overall survival.

CANCERS (2021)

添加到收藏夹

Article Oncology

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study

A. Raimondiy et al.

Summary: The study showed no significant differences in efficacy, safety, and quality of life between elderly and younger patients receiving anti-EGFR treatment. Female patients had a higher incidence of severe adverse events, while male patients were more likely to experience skin rash and hypomagnesemia.

ESMO OPEN (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Munenobu Kashiwa et al.

Summary: This study examined the cost-effectiveness of preventive skin care for skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer from the perspective of the Japanese healthcare payer. The results showed that the cost to effectiveness of preemptive treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type mCRC is not high.

JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology